Pandemic (H1N1) 2009 Influenza Update: Initial results from first clinical trial of GSK’s H1N1 adjuvanted vaccine

Issued: Monday 14 September 2009, London UKGlaxoSmithKline (GSK) today announced results from its first clinical trial assessing use of its pandemic (H1N1) adjuvanted vaccine. The results demonstrate that after one dose the candidate vaccine can provide a strong immune response which exceeds the immunogenicity criteria as defined by international licensing authorities for a pandemic influenza vaccine.